vinflunine + ixabepilone
Drugsolution for injection, IV, vinflunine: 250 to 320 mg/m2 + ixabepilone: 30 to 40 mg/m2, every 3 wks, variable duration
NCT Number: NCT00362830
The purpose of the study is to test how vinflunine interacts with ixabepilone in the human body.
Looking for future studies?
Notify MeHealthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
solution for injection, IV, vinflunine: 250 to 320 mg/m2 + ixabepilone: 30 to 40 mg/m2, every 3 wks, variable duration
Time frame: upon occurrence
Time frame: upon occurrence
Bristol-Myers Squibb
Industry
A Study of the Alternating Administration of Ixabepilone and Vinflunine Every Three Weeks in Patients With Advanced Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05510908
AIDS Related Lymphoma, AIDS-Related Kaposi Sarcoma
La Jolla, California, United States
View Trial DetailsNCT07766252
Cancer, Neoplasms
College Station, Texas, United States
View Trial DetailsNCT01445483
Brain Diseases, Brain Metastasis
Bethesda, Maryland, United States
View Trial DetailsNCT01498276
Cancer, Cardiovascular Diseases
Washington D.C., District of Columbia, United States
View Trial Details